MX2017013350A - Comprimido de ribociclib. - Google Patents

Comprimido de ribociclib.

Info

Publication number
MX2017013350A
MX2017013350A MX2017013350A MX2017013350A MX2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A
Authority
MX
Mexico
Prior art keywords
ribociclib
tablet
directed
present disclosure
coating
Prior art date
Application number
MX2017013350A
Other languages
English (en)
Spanish (es)
Inventor
Grandeury Arnaud
Gururajan Bindhumadhavan
Costa Rui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017013350A publication Critical patent/MX2017013350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017013350A 2015-04-16 2016-04-14 Comprimido de ribociclib. MX2017013350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
MX2017013350A true MX2017013350A (es) 2018-01-25

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013350A MX2017013350A (es) 2015-04-16 2016-04-14 Comprimido de ribociclib.

Country Status (31)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP4197530B1 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR20250009572A (enExample)
CN (2) CN115554257A (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (2) DK4197530T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (2) ES2938261T3 (enExample)
FI (2) FI3283058T3 (enExample)
HR (2) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (2) IL254818B1 (enExample)
LT (1) LT4197530T (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (2) PL3283058T3 (enExample)
PT (2) PT3283058T (enExample)
RS (1) RS67697B1 (enExample)
SG (1) SG11201708084PA (enExample)
SI (2) SI3283058T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3033086T1 (sl) 2013-08-14 2022-01-31 Novartis Ag Kombinirana terapija za zdravljenje raka
BR112017021283A2 (en) * 2015-04-16 2018-06-26 Novartis Ag ribocyclib tablet
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Crystalline form of ribociclib succinate
ES3061133T3 (en) 2019-08-26 2026-03-31 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021124104A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
IL293940B2 (en) 2019-12-16 2026-05-01 Lunella Biotech Inc Selective cancer drugs CDK4/6 inhibitors
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
MX2022015336A (es) * 2020-09-29 2023-01-11 Laboratorios Silanes S A De C V Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
US20240376096A1 (en) 2021-07-16 2024-11-14 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
KR20250163966A (ko) 2023-03-27 2025-11-21 노파르티스 아게 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
HU225964B1 (en) * 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
EA019094B1 (ru) 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CA2827027C (en) * 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
HUE052574T2 (hu) * 2012-07-13 2021-05-28 Oncternal Therapeutics Inc Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
DK2976106T3 (da) * 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
BR112017021283A2 (en) 2015-04-16 2018-06-26 Novartis Ag ribocyclib tablet
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
TW201642864A (zh) 2016-12-16
BR112017021283A2 (en) 2018-06-26
IL254818B1 (en) 2026-05-01
US10799506B2 (en) 2020-10-13
SI3283058T1 (sl) 2023-03-31
PL4197530T3 (pl) 2026-03-23
CN107530292A (zh) 2018-01-02
FI3283058T3 (fi) 2023-03-01
HRP20260123T1 (hr) 2026-03-13
EP3283058B1 (en) 2022-11-16
IL327430A (en) 2026-05-01
PE20180035A1 (es) 2018-01-09
US20230104792A1 (en) 2023-04-06
US20250134893A1 (en) 2025-05-01
PT4197530T (pt) 2026-02-05
EP3283058A1 (en) 2018-02-21
ECSP17075052A (es) 2018-02-28
CL2017002593A1 (es) 2018-05-18
AU2022215155A1 (en) 2022-09-01
HUE061213T2 (hu) 2023-05-28
EP4197530B1 (en) 2025-11-12
AU2016248017A1 (en) 2017-10-19
LT4197530T (lt) 2026-02-25
KR20250009572A (ko) 2025-01-17
FI4197530T3 (fi) 2026-02-03
AU2020250190A1 (en) 2020-11-05
RS67697B1 (sr) 2026-02-27
TN2017000422A1 (en) 2019-01-16
US20200390771A1 (en) 2020-12-17
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
KR102750931B1 (ko) 2025-01-09
CA2982425A1 (en) 2016-10-20
SI4197530T1 (sl) 2026-03-31
AU2019201929B2 (en) 2020-07-09
AU2024227794A1 (en) 2024-11-21
AR104257A1 (es) 2017-07-05
DK4197530T3 (da) 2026-02-09
JP2018514523A (ja) 2018-06-07
WO2016166703A1 (en) 2016-10-20
KR20170137101A (ko) 2017-12-12
HRP20230053T1 (hr) 2023-03-03
CO2017010510A2 (es) 2018-03-20
PL3283058T3 (pl) 2023-03-20
EP4620458A2 (en) 2025-09-24
EP4197530A1 (en) 2023-06-21
ES3062263T3 (en) 2026-04-09
ES2938261T3 (es) 2023-04-05
EP4620458A3 (en) 2025-10-22
PT3283058T (pt) 2023-02-03
CN107530292B (zh) 2022-11-01
US20250127785A1 (en) 2025-04-24
EA201792290A1 (ru) 2018-02-28
PH12017501820A1 (en) 2018-04-23
US20250090531A1 (en) 2025-03-20
AU2019201929A1 (en) 2019-04-11
IL254818A0 (en) 2017-12-31
CA2982425C (en) 2023-10-31
SG11201708084PA (en) 2017-10-30
US12064434B2 (en) 2024-08-20
DK3283058T3 (da) 2023-02-13
AU2022215155B2 (en) 2024-08-01
CN115554257A (zh) 2023-01-03

Similar Documents

Publication Publication Date Title
PH12017501820A1 (en) Ribociclib tablet
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EP3038539A4 (en) Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
EP3130592A4 (en) Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
EP2986681A4 (en) An aqueous coating composition
IN2015DN01286A (enExample)
IL280641A (en) Converted benzimidazoles as PAD4 inhibitors
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
IL257340A (en) Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals
PH12015502783A1 (en) Delayed release cysteamine bead formulation
EP3256450A4 (en) Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
EP3124486A4 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
EP3256672A4 (en) Access-control fixture lock
CA3242369A1 (en) Tablets having discontinuous coated regions
SG11201705533SA (en) Levelling compound, its use and manufacture
GB2543709A (en) Pharmaceutical agent
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
EP3325564A4 (en) AQUEOUS COATING COMPOSITION
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EP3303319B8 (en) Derivatives of 1,2,3-triazolyl cyclohexan-1-ol and its use
EP3024427A4 (en) Derivatives of 2,2,6-trimethylcyclohexane-carboxylate
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt